{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:23:03Z","timestamp":1791091383108,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T00:00:00Z","timestamp":1386633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/npp.2013.335","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T10:43:14Z","timestamp":1386672194000},"page":"1399-1408","source":"Crossref","is-referenced-by-count":93,"title":["Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial"],"prefix":"10.1038","volume":"39","author":[{"given":"Kamilla W","family":"Miskowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens D","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Ehrenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars V","family":"Kessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,10]]},"reference":[{"key":"BFnpp2013335_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7007-6-37","volume":"6","author":"B Adamcio","year":"2008","unstructured":"Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F et al (2008). Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6: 37.","journal-title":"BMC Biol"},{"key":"BFnpp2013335_CR2","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"ML Brines","year":"2000","unstructured":"Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al (2000). Erythropoietin crosses the blood\u2013brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526\u201310531.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2013335_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1046\/j.1360-0443.2000.9545759.x","volume":"95","author":"HV Curran","year":"2000","unstructured":"Curran HV, Morgan C (2000). Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95: 575\u2013590.","journal-title":"Addiction"},{"key":"BFnpp2013335_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/0028-3908(88)90189-X","volume":"27","author":"W Danysz","year":"1988","unstructured":"Danysz W, Wroblewski JT, Costa E (1988). Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27: 653\u2013656.","journal-title":"Neuropharmacology"},{"key":"BFnpp2013335_CR5","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/brain\/awm203","volume":"130","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M et al (2007a). Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130: 2577\u20132588.","journal-title":"Brain"},{"key":"BFnpp2013335_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.mp.4001907","volume":"12","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S et al (2007b). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12: 206\u2013220.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2013335_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archpsyc.63.10.1121","volume":"63","author":"ML Furey","year":"2006","unstructured":"Furey ML, Drevets WC (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63: 1121\u20131129.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2013335_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.biopsych.2008.12.005","volume":"66","author":"MJ Girgenti","year":"2009","unstructured":"Girgenti MJ, Hunsberger J, Duman CH, Sathyanesan M, Terwilliger R, Newton SS (2009). Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 66: 267\u2013274.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2013335_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jad.2010.11.011","volume":"134","author":"BJ Hasselbalch","year":"2011","unstructured":"Hasselbalch BJ, Knorr U, Kessing LV (2011). Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disorder 134: 20\u201331.","journal-title":"J Affect Disorder"},{"key":"BFnpp2013335_CR10","first-page":"1029","volume":"18","author":"A K\u00e4stner","year":"2012","unstructured":"K\u00e4stner A, Grube S, El-Kordi A, Stepniak B, Friedrichs H, Sargin D et al (2012). Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia. Mod Med 18: 1029\u20131040.","journal-title":"Mod Med"},{"key":"BFnpp2013335_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.neuropharm.2010.09.025","volume":"60","author":"C Leconte","year":"2011","unstructured":"Leconte C, Bihel E, Lepelletier FX, Bouet V, Saulnier R, Petit E et al (2011). Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 60: 354\u2013364.","journal-title":"Neuropharmacology"},{"key":"BFnpp2013335_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.1098313","volume":"305","author":"M Leist","year":"2004","unstructured":"Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305: 239\u2013242.","journal-title":"Science"},{"key":"BFnpp2013335_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0006-3223(03)00117-3","volume":"53","author":"HK Manji","year":"2003","unstructured":"Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N et al (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53: 707\u2013742.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2013335_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1460-9568.1996.tb01252.x","volume":"8","author":"HH Marti","year":"1996","unstructured":"Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V et al (1996). Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666\u2013676.","journal-title":"Eur J Neurosci"},{"key":"BFnpp2013335_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00213-011-2511-1","volume":"219","author":"KW Miskowiak","year":"2012","unstructured":"Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV (2012). Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 219: 687\u2013698.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2013335_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.biopsych.2007.01.011","volume":"62","author":"K Miskowiak","year":"2007","unstructured":"Miskowiak K, O'Sullivan U, Harmer CJ (2007a). Erythropoietin reduces neural and cognitive processing of fear in human models of antidepressant drug action. Biol Psychiatry 62: 1244\u20131250.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2013335_CR17","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1523\/JNEUROSCI.5013-06.2007","volume":"27","author":"K Miskowiak","year":"2007","unstructured":"Miskowiak K, O'Sullivan U, Harmer CJ (2007b). Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 27: 2788\u20132792.","journal-title":"J Neurosci"},{"key":"BFnpp2013335_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-007-0907-8","volume":"195","author":"K Miskowiak","year":"2007","unstructured":"Miskowiak K, Inkster B, Selvaraj S, Goodwin G, Harmer C (2007c). Erythropoietin has no effect on hippocampal response during memory retrieval 3 days post-administration. Psychopharmacology (Berl) 195: 451\u2013453.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2013335_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00221-007-1102-1","volume":"184","author":"K Miskowiak","year":"2008","unstructured":"Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ (2008). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 184: 313\u2013321.","journal-title":"Exp Brain Res"},{"key":"BFnpp2013335_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1745-6215-11-97","volume":"11","author":"KW Miskowiak","year":"2010","unstructured":"Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J et al (2010). Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 11: 97.","journal-title":"Trials"},{"key":"BFnpp2013335_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","volume":"370","author":"S Moussavi","year":"2007","unstructured":"Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370: 851\u2013858.","journal-title":"Lancet"},{"key":"BFnpp2013335_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000207456","volume":"42","author":"M Mur","year":"2009","unstructured":"Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E (2009). Influence of clinical and neuropsychological variables on the psychosocial and occupational outcome of remitted bipolar patients. Psychopathology 42: 148\u2013156.","journal-title":"Psychopathology"},{"key":"BFnpp2013335_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1023\/B:QURE.0000018485.05372.d6","volume":"13","author":"V Noerholm","year":"2004","unstructured":"Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P (2004). Quality of life in the Danish general population\u2014normative data and validity of WHOQOL-BREF using Rasch and item response theory models. Qual Life Res 13: 531\u2013540.","journal-title":"Qual Life Res"},{"key":"BFnpp2013335_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01.nmd.0000110280.19284.47","volume":"192","author":"MA Posternak","year":"2004","unstructured":"Posternak MA, Young D, Sheeran T, Chelminski I, Franklin CL, Zimmerman M (2004). Assessing past treatment history: test-retest reliability of the Treatment Response to Antidepressant Questionnaire. J Nerv Ment Dis 192: 95\u2013102.","journal-title":"J Nerv Ment Dis"},{"key":"BFnpp2013335_CR25","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905\u20131917.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2013335_CR26","first-page":"10","volume":"62","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA (2001). The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62: 10\u201317.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2013335_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.bpa.2010.10.005","volume":"24","author":"D Sargin","year":"2010","unstructured":"Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H (2010). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol 24: 573\u2013594.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"BFnpp2013335_CR28","volume-title":"Rey Auditory Verbal Learning Test\u2014A Handbook","author":"M Schmidt","year":"2004","unstructured":"Schmidt M (2004) Rey Auditory Verbal Learning Test\u2014A Handbook. Western Psychological Services: Los Angeles, LA, USA."},{"key":"BFnpp2013335_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","volume":"6","author":"AL Siren","year":"2009","unstructured":"Siren AL, Fasshauer T, Bartels C, Ehrenreich H (2009). Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6: 108\u2013127.","journal-title":"Neurotherapeutics"},{"key":"BFnpp2013335_CR30","volume-title":"A Compendium of Neuropsychological Tests. Administration, Norms, and Commentary","author":"E Strauss","year":"2006","unstructured":"Strauss E, Sherman EMS, Spreen O (2006) A Compendium of Neuropsychological Tests. Administration, Norms, and Commentary. Oxford University Press: New York, NY, USA."},{"key":"BFnpp2013335_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA Jr., Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856\u2013864.","journal-title":"Arch Gen Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2013335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2013335","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2013335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:46:51Z","timestamp":1684453611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2013335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFnpp2013335"],"URL":"https:\/\/doi.org\/10.1038\/npp.2013.335","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,10]]}}}